Market closed
Sanofi/€SAN
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Ticker
€SAN
Sector
Trading on
PAR
Industry
Pharmaceuticals
Headquarters
Employees
86,088
Website
Sanofi Metrics
BasicAdvanced
€112B
Market cap
24.83
P/E ratio
€3.59
EPS
0.45
Beta
€3.76
Dividend rate
4.22%
Dividend yield
Price and volume
Market cap
€112B
Beta
0.45
52-week high
€104.92
52-week low
€84.93
Average daily volume
1.5M
Dividend rate
€3.76
Financial strength
Total debt to equity
32.537
Interest coverage (TTM)
12.99%
Management effectiveness
Valuation
Price to earnings (TTM)
24.827
Price to revenue (TTM)
2.302
Price to book
1.53
Price to tangible book (TTM)
24.86
Dividend yield (TTM)
4.22%
Forward dividend yield
4.22%
Growth
Revenue change (TTM)
6.01%
Earnings per share change (TTM)
-50.24%
3-year revenue growth (CAGR)
7.96%
3-year earnings per share growth (CAGR)
-9.86%
What the Analysts think about Sanofi
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Sanofi Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Sanofi Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Sanofi News
AllArticlesVideos
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
GlobeNewsWire·3 days ago
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Reuters·3 days ago
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SAN) has a market cap of €112B as of December 15, 2024.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SAN) stock is 24.83 as of December 15, 2024.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SAN) stock pays dividends to shareholders. As of December 15, 2024, the dividend rate is €3.76 and the yield is 4.22%. Sanofi has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SAN) dividend payment date is unconfirmed.
What is the beta indicator for Sanofi?
Sanofi (SAN) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.